On November 25, 2015, Amgen Inc. submitted a Biologics License Application (BLA) for ABP 501, the company’s biosimilar candidate to Humira® (adalimumab). Earlier this week, Amgen announced that its BLA has been accepted for review by the FDA.
In its press release, which was published on Tuesday, January 26, Amgen stated that the BLA “is based on analytical, clinical, and pharmacokinetic data.” In addition, the company stated that “Phase 3 comparative efficacy and safety studies were conducted in both moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis. The Phase 3 studies met their primary endpoints showing clinical equivalence to adalimumab. Safety and immunogenicity of ABP 501 were also comparable to adalimumab. Data to support the transition of adalimumab patients to ABP 501 are included in the submission.”
Amgen’s ABP 501 has a BsUFA target action date of September 25, 2016. It will be very interesting to see the outcome of FDA’s review later this year.
October 5, 2015
Sandoz, the generic pharmaceuticals division of Novartis, is the global leader in biosimilar products. On March 6, 2015, FDA approved Zarxio, a biosimilar version of Amgen’s Neupogen (filgrastim)...
May 26, 2016
Earlier this week Samsung Bioepis announced that FDA has accepted for review its BLA for SB2, a biosimilar version of Remicade (infliximab). SB2 is indicated for the treatment of rheumatoid...
June 6, 2016
On August 28, 2015, FDA announced the availability of a draft guidance, entitled “Nonproprietary Naming of Biological Products,” which established a naming convention for biological products. The...